Palonosetron Hydrochloride in the Prevention and Treatment of Postoperative Nausea and Vomiting

@inproceedings{Wallenborn2010PalonosetronHI,
  title={Palonosetron Hydrochloride in the Prevention and Treatment of Postoperative Nausea and Vomiting},
  author={J. Wallenborn and P. Kranke},
  year={2010}
}
On the strength of two phase III clinical trials, palonosetron hydrochloride was granted FDA approval in March 2008 for the prevention of postoperative nausea and vomiting (PONV) in the period up to 24 hours after surgery. Palonosetron is superior to the established first-generation 5-hydroxytryptamin-3 receptor antagonists (5-HT3-RAs) in respect of pharmacokinetic data such as a high receptor binding affinity (pKi = 10.45) and a prolonged mean elimination half-life (40 hours). Clinically… Expand
Comparison between palonosetron and ramosetron to prevent postoperative nausea and vomiting in patients undergoing laparoscopic surgery
TLDR
Palonosetron given as a prophylaxis for post-operative nausea and vomiting (PONV) in patients undergoing for laparoscopic surgeries seems to have better antiemetic effect over ramosetrons. Expand
Palonosetron versus ondansetron for prevention of postoperative nausea and vomiting during middle ear surgery: a double-blind, randomized, comparative trial
TLDR
Palonosetron is a good antiemetic alternative during anesthesia with minimal side effects and showed significant decrease in nausea score in comparison with ondansetron in group 1. Expand
Palonosetron versus ondansetron for prevention of postoperative nausea and vomiting during middle ear surgery: a double-blind, randomized, comparative trial
TLDR
The aim of this study was to assess the effi cacy and safety of palonosetron versus ondansetron for PONV during middle ear surgery (MES). Expand
Palonosetron and palonosetron plus dexamethasone to prevent postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: A prospective, randomized, double-blind comparative study
TLDR
The palonosetron and dexamethasone combination was not more effective than palonOSetron alone in the prevention of PONV, in patients undergoing LC under GA. Expand
Update on the Management of Postoperative Nausea and Vomiting
TLDR
New antiemetic drug developments, formulations, guidelines, risk evaluation, and controversies have occurred in the area of postoperative nausea and vomiting (PONV) to improve understanding of the prevention and treatment of PONV in the postanesthesia care unit and after discharge home or to the hospital ward. Expand
Ondansetron, ramosetron, or palonosetron: Which is a better choice of antiemetic to prevent postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy?
TLDR
Ramosetron 0.3 mg iv was more effective than palonosetronic 0.075 mg for prophylaxis of PONV in high-risk patients undergoing LC in the early postoperative period, but there was no significant difference in the overall incidence of nausea suffered. Expand
A Clinical Comparative Study of Oral Aprepitant and Injection Palonosetron for Prevention of Postoperative Nausea and Vomiting in Patients of Laparoscopic Cholecystectomy under General Anaesthesia
TLDR
Palonosetron and Aprepitant both are the effective in reducing the incidence of post-operative nausea and vomiting up to 24 hours, when given prior to induction of general anaesthesia. Expand
Comparative Pharmacology and Guide to the Use of the Serotonin 5-HT3 Receptor Antagonists for Postoperative Nausea and Vomiting
TLDR
The 5-HT3 receptor antagonists play an important role to help prevent PONV and PDNV in perioperative care pathways such as Enhanced Recovery After Surgery (ERAS). Expand
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
BACKGROUND Postoperative nausea and vomiting (PONV) is a common adverse effect of anaesthesia and surgery. Up to 80% of patients may be affected. These outcomes are a major cause of patientExpand
Safety and efficacy of commonly used antiemetics
TLDR
Antihistamines, phenothiazines, corticosteroids, benzamindes, anticholinergic, neurokinin-1 antagonists, 5-HT3 receptor antagonist and cannabinoids are discussed. Expand
...
1
2
...

References

SHOWING 1-10 OF 81 REFERENCES
Pharmacokinetic and Safety Evaluation of Palonosetron, a 5‐Hydroxytryptamine‐3 Receptor Antagonist, in U.S. and Japanese Healthy Subjects
TLDR
The pharmacokinetics of palonosetron appeared to be independent of dose, with no dose adjustment required in Japanese subjects, and may provide a clinical advantage over other 5‐HT3 antagonists. Expand
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
TLDR
A single i.v. dose of palonosetron 0.25 mg was significantly superior to ondansetron 32 mg in the prevention of acute and delayed CINV and both treatments were well tolerated. Expand
Management of postoperative nausea and vomiting: focus on palonosetron
TLDR
Palonosetron is a second-generation 5-HT3 antagonist that has recently been approved for prophylaxis against PONV and has unique structural, pharmacological and clinical properties that distinguish it from other agents in its class. Expand
Prevention of postoperative nausea and vomiting by metoclopramide combined with dexamethasone: randomised double blind multicentre trial
TLDR
The addition of 50 mg metoclopramide to 8 mg dexamethasone (given intraoperatively) is an effective, safe, and cheap way to prevent postoperative nausea and vomiting. Expand
The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial
TLDR
A single dose (0.25 mg) of palonosetron is not inferior to a single dose of granisetron in preventing CIV and possesses an acceptable safety profile in the Chinese population. Expand
[Postoperative nausea and vomiting--what's new in anti-emetic pharmacotherapy?].
TLDR
Palonosetron is a new representative of the serotonin-3 receptor antagonists but without the hoped for superiority on the 2nd and 3rd postoperative days, however, available data do suggest that palanosetron does not prolong the OT (c) interval. Expand
Pharmacokinetic Evaluation and Safety Profile of a 15‐Minute Versus 30‐Second Infusion of Palonosetron in Healthy Subjects
TLDR
The pharmacokinetics of palonosetron infused over 15 minutes is well tolerated, with an AUC0‐∞ equivalent to a 30‐second infusion, and the plasma elimination half‐life, total body clearance, and apparent volume of distribution at steady state were similar for both treatments. Expand
The Efficacy of RS-25259, a Long-Acting Selective 5-HT3 Receptor Antagonist, for Preventing Postoperative Nausea and Vomiting After Hysterectomy Procedures
TLDR
RS-25259 30 [micro sign]g/kg IV was effective in reducing the incidence of PONV after major gynecologic surgery, but the occurrence of headaches with the larger doses of RS-25 259 is a concern. Expand
A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Three Different Doses of Palonosetron Versus Placebo for Preventing Postoperative Nausea and Vomiting
TLDR
A single 0.075-mg IV dose of palonosetron significantly increased the CR rate from 0 to 24 h, decreased nausea severity and patients experienced significantly less interference in their postoperative function due to PONV. Expand
A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Three Different Doses of Palonosetron Versus Placebo in Preventing Postoperative Nausea and Vomiting Over a 72-Hour Period
TLDR
A single 0.075-mg IV dose of palonosetron effectively reduced the severity of nausea and delayed the time to emesis and treatment failure in the inpatient surgical setting; lower doses were not as effective. Expand
...
1
2
3
4
5
...